Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland

Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Duchosal, Michel A; Heim, Dominik; Hess, Urs; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Taverna, Christian; Zander, Thilo; Renner, Christoph

doi:10.4414/smw.2015.14100

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland
Authors		Samaras, Panagiotis Bargetzi, Mario Betticher, Daniel C Duchosal, Michel A Heim, Dominik Hess, Urs Ketterer, Nicolas Lerch, Erika Matthes, Thomas Mey, Ulrich Pabst, Thomas Taverna, Christian Zander, Thilo Renner, Christoph show all authors [1 - 14]
Published in		Swiss medical weekly. 2015, vol. 145, w14100
Abstract		The availability of drugs such as thalidomide, bortezomib and lenalidomide changed the landscape in myeloma treatment and has extended the median survival up to 10 years with a substantial improvement in quality of life. This development prompted a Swiss expert panel to re-evaluate the current status and formulate updated clinical recommendations for the diagnosis and treatment of plasma cell myeloma. These recommendations should help clinicians in their decision making to achieve the best outcome based on currently available data.
Identifiers		DOI: 10.4414/smw.2015.14100 PMID: 25999239
Full text		Article (Published version) (778 Kb) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine
Research group		Analyses cellulaires et moléculaires des hémopathies malignes (929)
Citation (ISO format)		SAMARAS, Panagiotis et al. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. In: Schweizerische medizinische Wochenschrift, 2015, vol. 145, p. w14100. doi: 10.4414/smw.2015.14100 https://archive-ouverte.unige.ch/unige:79945